hs-CRP (high-sensitivity C-reactive protein)

Reference ranges

Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.

Peptide relevance

BPC-157 has anti-inflammatory effects in animal models — could lower CRP. Tirzepatide / Semaglutide reduce CRP in obese patients (driven mostly by weight loss). CJC-1295 + Ipamorelin: no consistent CRP effect. KEY CONFOUNDERS: any acute infection in last 2 weeks can raise CRP 10-100x; intense training in last 48h raises CRP 2-5x; obesity is a baseline elevator; smoking; recent surgery or injury.

Peptides that influence this marker

Documented to affect this marker. Click through for the full evidence-tiered profile.

• Tier 2 — Human observationalBPC-157↓· 6–12 weeks
  Gastric pentadecapeptide

  Anti-inflammatory in animal models — broad cytokine suppression; human CRP data sparse

• GHK-Cu
  Copper tripeptide

  Copper-binding tripeptide — anti-inflammatory and wound-healing effects (mostly topical)

• Tier 2 — Human observationalGlow↓· 6–12 weeks
  Blend

  Inflammation overlay, not a direct action marker.

• KPV
  α-MSH C-terminal tripeptide

  α-MSH fragment — anti-inflammatory in IBD models; oral and topical use

• Tier 2 — Human observationalKlow↓· 6–12 weeks
  Blend

  Inflammation overlay — KPV + TB-500 anti-inflammatory action makes this more relevant than for the repair-only blends.

• Tier 2 — Human observationalLL-37↓· 4–8 weeks
  Antimicrobial peptide

  General inflammation overlay during infection resolution; not LL-37-specific.

• Larazotide
  Tight-junction modulator (gut)

  Tight-junction modulator — reduces gut-derived systemic inflammation in celiac

• SS-31 (Elamipretide)
  Mitochondrial-targeted peptide

  Mitochondrial-targeted antioxidant — reduces ROS-driven inflammation

• Tier 2 — Human observationalTB-500↓· 6–12 weeks
  Thymosin Beta-4 fragment

  Inflammation overlay, not a direct action marker.

• Thymosin Alpha-1
  Immunomodulatory peptide

  Immune-modulator — can lower CRP in chronic inflammatory conditions

• Tier 2 — Human observationalWolverine↓· 6–12 weeks
  Blend

  Inflammation overlay, not a direct action marker.